Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma

Cancer

Volumn 117, Issue 2, 2011, Pages 421-434

  Nemeth, Katie M ^a   Federico, Sara ^a   Carcaboso, Angel M ^a   Shen, Ying ^a   Schaiquevich, Paula ^a,e   Zhang, Jiakun ^a   Egorin, Merrill ^b   Stewart, Clinton ^a   Dyer, Michael A ^a,c,d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

carboplatin; retinoblastoma; topotecan; translational research

Indexed keywords

CARBOPLATIN; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; EYE TOXICITY; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; SYSTEMIC THERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CONJUNCTIVA; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; RATS; RETINAL NEOPLASMS; RETINOBLASTOMA; TOPOTECAN; VISUAL ACUITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650972381     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25574     Document Type: Article

References (13)

1. Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, Md: National Institutes of Health; 1999.
2. Dyer MA, Rodriguez-Galindo C, Wilson MW., Use of preclinical models to improve treatment of retinoblastoma [serial online]. PLoS Med. 2005; 2: e332.
3. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006; 444: 61-66.
4. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in 2 new rodent models of retinoblastoma. Clin Cancer Res. 2005; 11: 7569-7578.
5. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002; 20: 88-95.
6. Abramson DH, Frank CM, Dunkle IJ., A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999; 106: 1947-1950.
7. Zhang J, Schweers B, Dyer MA., The first knockout mouse model of retinoblastoma. Cell Cycle. 2004; 3: 952-959.
8. McFall RC, Sery TW, Makadon M., Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res. 1977; 37: 1003-1010.
9. Shih CS, Laurie N, Holzmacher J, et al. AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models. Neuromolecular Med. 2009; 11: 43-52.
10. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999; 5: 3617-3631.
11. D'Argenio DZ, Schumitzky A., ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles, Calif: Biomedical Simulations Resource; 2006.
12. Prusky GT, Alam NM, Beekman S, Douglas RM., Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci. 2004; 45: 4611-4616.
13. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009; 50: 1492-1496.